Pulse Biosciences, Inc. PLSE
Set alert
As of Nov 2, 11:15 AM ET
- YTD
- +287.04%
- 1 year
- +213.88%
- Open
- 52.40
- Prev close
- 52.24
- Mkt cap
- 3.79B
- Vol
- 75.53K
- Avg vol
- 503.42K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 51.32
- High
- 53.70
- Forward P/E
- -44.65
- Beta
- 1.57
- Short ratio
- 5.88
- Inst. own
- 15.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 50.99
- 200-d avg
- 31.16
- 1y target
- 62.33
5D chart
Signals (99)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 9:55 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:50 AM | 1 hour ago |
| MACD: Buy Signal | Nov 2, 9:45 AM | 1 hour ago |
| MACD: Sell Signal | Nov 2, 9:40 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:05 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:55 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:35 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:20 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:50 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 6 days ago |
News
3 days ago businesswire.com
Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™)…
1 week ago businesswire.com
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™)…
2 weeks ago defenseworld.net
Varex Imaging (NASDAQ:VREX) vs. Pulse Biosciences (NASDAQ:PLSE) Head to Head Review
Pulse Biosciences (NASDAQ: PLSE - Get Free Report) and Varex Imaging (NASDAQ: VREX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
2 weeks ago gurufocus.com
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation⢠(nano-PFA or nsPFAâ¢
-
2 weeks ago benzinga.com
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the…
2 weeks ago businesswire.com
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™)…
-
2 weeks ago benzinga.com
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.
3 weeks ago businesswire.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™)…
3 weeks ago businesswire.com
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™)…
3 weeks ago businesswire.com
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today…
-
3 weeks ago benzinga.com
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $43 to $58.
3 weeks ago defenseworld.net
Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20
Shares of Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the firm, Marketbeat Ratings…
1 month ago benzinga.com
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
1 month ago benzinga.com
This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.
-
1 month ago benzinga.com
BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70
BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $70.
-
1 month ago benzinga.com
Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold
On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distribution agreement (the "Sales Agreement") with Mizuho Securities USA LLC ("Mizuho") as sales agent,
1 month ago gurufocus.com
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse⢠technology using proprietary Nanosecond Pulsed Field Ablation⢠(nanosecond PFA or nsP
-
1 month ago benzinga.com
Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones…
1 month ago businesswire.com
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)…
1 month ago benzinga.com
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
1 month ago fool.com
Why Pulse Biosciences Stock Popped Today
An analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in particular is ripe for disruption by the company.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
-
1 month ago benzinga.com
Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73
Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $73.
1 month ago businesswire.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today…
2 months ago defenseworld.net
Deutsche Bank AG Takes Position in Pulse Biosciences, Inc $PLSE
Deutsche Bank AG purchased a new stake in Pulse Biosciences, Inc (NASDAQ: PLSE) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund…
2 months ago benzinga.com
Top 3 Health Care Stocks That May Keep You Up At Night In Q3
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
2 months ago defenseworld.net
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.2% in the undefined quarter, according to the company in its most recent disclosure with the…
2 months ago defenseworld.net
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Here’s Why
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The stock traded as high as $48.10 and last traded at $46.00, with a volume of…
2 months ago businesswire.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today…
2 months ago benzinga.com
This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets for PMT, ALAB.
2 months ago benzinga.com
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Workday downgraded, price target cut.
2 months ago benzinga.com
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's page. Analysts have positive views on ONTO stock.
-
2 months ago benzinga.com
Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58
Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $58.
2 months ago marketbeat.com
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions,…
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $32 to $43.
2 months ago seekingalpha.com
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for…
-
2 months ago benzinga.com
Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.28) per share from the…
4 months ago benzinga.com
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
-
5 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32
Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $32.
-
5 months ago benzinga.com
Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan…
-
6 months ago benzinga.com
Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
Pulse Biosciences Enrolls First Patient In Its NANOPULSE-AF Study Of nPulse Cardiac Catheter System For Recurrent, Drug-Resistant, Symptomatic Paroxysmal Atrial Fibrillation
The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research…
-
7 months ago benzinga.com
Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib).
Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and
-
7 months ago benzinga.com
Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
8 months ago benzinga.com
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
-
8 months ago benzinga.com
Pulse Biosciences Q4 EPS $(0.26) Beats $(0.31) Estimate, Sales $264.000K Beat $250.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 16.13 percent increase over losses of…
-
8 months ago benzinga.com
Earnings Scheduled For February 19, 2026
Earnings Scheduled For February 19, 2026